(VIANEWS) – MITHRA (BEL 20: MITRA.BR) shares surged 9.63% to EUR2.22 at 15:27 EST Wednesday after suffering three consecutive sessions of losses, seemingly going against the current downward trend seen across BEL 20, which was down 0.84% over three days to EUR3,633.39. MITHRA’s last close was EUR2.03, over 73.32% below its 52-week high of EUR7.59.
About MITHRA
Mithra Pharmaceuticals SA specializes in the development, production, and sale of complex therapeutics related to contraception, menopause and hormone-dependent cancers. Estelle, a combined oral contraceptive that has undergone phase III clinical trials, and Donesta (an estetrol-based oral hormone treatment currently in phase III clinical trials) are products from its product portfolio that address neuroprotection and wound healing respectively. Mithra Pharmaceuticals SA was founded in 1999 and headquartered in Liege, Belgium. Since that time it has developed and marketed various contraceptive vaginal rings as well as Tibelia for hormone therapy in menopause; Zoreline for biodegradable subcutaneous implants targeting prostate and breast cancers as well as benign gynecological indications; polymeric forms, implants, sterile injectable products and hormonal tablets among others.
Yearly Analysis
MITHRA’s current stock value of EUR2.22 is considerably below its 52-week high of EUR7.59, suggesting a potential buying opportunity for investors. Investors should also keep sales growth prospects in mind; MITHRA expects this year’s sales growth rates to be high at 574 % and negative by 29 7% for next year.
Negative sales growth expectations may cause investors to worry, suggesting that revenue may slow or even decline over the next year. To accurately evaluate this stock as an investment opportunity, investors must also take into account other aspects such as earnings growth, profitability and competitive positioning of its fundamentals – like earnings growth.
Before making any investment decisions, investors must exercise extreme caution and conduct due diligence to make an informed decision. It’s vitally important that investors carefully examine a company’s financial statements, industry trends and market conditions before determining if its stock would make a suitable long-term investment option.
Technical Analysis
MITHRA stock has experienced an upward trend recently, as evidenced by its current price remaining above its 50-day moving average of EUR2.16 but below its 200-day moving average of EUR2.85. Today’s volume reported was 387225 which represents 31.32% more than its average volume of 294866.
Volatility on the stock has been fairly consistent over the last three time periods, averaging positive 0.133% weekly, negative 1.888% monthly and positive 5.0% quarterly respectively. Its highest amplitude of average volatility reached 1.61% weekly, 2.966% monthly and 5.00% quarter-to-quarter.
The stochastic oscillator, an indicator that measures overbought and oversold conditions for stocks, shows that MITHRA’s shares are currently overbought (>=80), suggesting further growth potential for their future performance.
Quarter Analysis
Based on available data, this company has seen impressive year-on-year quarterly revenue growth of 428.6% year over year over quarter. This indicates that revenue has steadily been rising year over year – currently standing at 67M – indicating it may provide an excellent investment opportunity for those seeking high revenue growth companies. It should be noted however, that such rapid revenue expansion may not be sustained over time and investors should conduct additional due diligence research in order to assess overall financial health as well as potential growth prospects of this organization.
Equity Analysis
According to available information, MITHRA currently has an Earnings Per Share ratio of EUR-1.22, indicating that it is currently not producing profits for its shareholders.
Return on Equity in the past twelve months was negative -176.58%, an alarming sign for investors. It shows that shareholders’ capital isn’t being effectively utilized to generate profits for shareholders’ benefit – which should concern shareholders as a whole.
Given MITHRA’s negative EPS and return on equity figures, potential investors should use caution in making any decision to invest in MITHRA. Before doing so, they may wish to review its financial statements and industry trends to gain an in-depth knowledge of its health and growth potential.
More news about MITHRA (MITRA.BR).
